Introduction
The development of effective therapy for advanced gastric cancer is still slow and no globally acceptable standard regimen has been established yet. However, recent randomized trials in this fi eld have achieved prolonged survival as compared with results in such trials in the 1990s. In Japan, two recent trials, the Japan Clinical Oncology Group (JCOG) 9912 trial [1] (in which the S-1 arm showed optimum survival) and the SPIRITS trial [2] (in which the S1-plus-cisplatin arm showed optimum survival) showed markedly longer median survival times (MSTs) than that seen in the previous JCOG trial (9205) [3] . Considering these results, S-1 plus cisplatin would be a most reasonable standard regimen for advanced gastric cancer in Japan. However, there still remain questions to be elucidated in the near future: whether S-1 plus cisplatin is superior to the most commonly used regimen worldwide -5-fl uorouracil (5-FU) and cisplatin -and whether cisplatin is the best partner for S-1. These issues will be resolved by obtaining the results of other ongoing trials, such as the FLAGS (5-FU + cisplatin vs S-1 + cisplatin), TOP002 (S-1 vs S-1+ irinotecan), and JACCRO GC-03 (S-1 vs S-1 + docetaxel) trials.
There are two major approaches to achieve further progress in the treatment of advanced gastric cancer. The fi rst is to optimize conventional cytotoxic agents (regimens) in the continuum of the treatment. The second approach is to incorporate new active agents, particularly molecular targeting agents. These two directions will be the most common approaches for most investigators in the near future, and some of them have already been initiated.
Optimization of conventional cytotoxic agents
The JCOG 9912 and SPIRITS trials demonstrated favorable survival in all arms, ranging from 10 to 13 Abstract According to the results of two recent randomized studies of treatment for metastatic gastric cancer in Japan, S-1 could replace infusional 5-fl uorouracil and S-1 plus cisplatin showed a signifi cant survival advantage over S-1 monotherapy, with a favorable toxicity profi le. However, no globally accepted standards have been established yet and we have to wait for the results of other ongoing international studies, including studies of S-1 and its combinations, to achieve such standards. There are two major approaches to achieve further progress in the treatment of advanced gastric cancer. The fi rst is to optimize the use of conventional cytotoxic agents (regimens) in the continuum of treatment for this disease. Several randomized studies of such regimens as second-line treatments are being planned in Japan, for which defi nitions of eligibility criteria and primary endpoints should be fully discussed in the design of the protocols. The second approach is to incorporate new active agents, particularly molecular targeting agents. Several molecular targeting agents that have shown survival advantages in patients with other tumor types are now under investigation for the treatment of gastric cancer in international randomized studies, including Japan and Korea. The next generation of targeting agents is also being evaluated in early clinical studies. Biological research has become essential for developing new targeting agents. For such biological studies, the tumor tissues of gastric cancer are easily obtainable via endoscopy, and such studies may constitute new frontiers in biological therapy. We expect that these studies will provide not only further clinical advantages but that they will also lead to tailored medicine.
months. However, these favorable fi ndings seemed to be a result not only of the effi cacy of fi rst-line therapy but also to result from second-line or subsequent therapy. Even with S-1 plus cisplatin, the median progression-free survival (PFS) was only 6 months, while an additional 7 months' survival was obtained by the subsequent treatments. All of the other arms in the two studies also showed average of around 7 months' survival after failure of the fi rst-line regimen. These survivals after the failure of fi rst-line therapy are considered to be longer than those in recently published randomized studies from other countries, which had a survival range of 3 to 5 months (Table 1) [1, 2, [4] [5] [6] [7] . One of the reasons why the Japanese studies had favorable survivals could be differences in eligibility criteria and baseline characteristics. The studies in Japan included patients without measurable metastatic disease, while the trials from the other countries usually excluded such patients. However, differences between the Japanese and non-Japanese trials in the proportions of the patient populations who received second-line chemotherapy seemed to have more impact on survival. For instance, more than 70% of patients in the JCOG 9912 [1] and the SPIRITS [2] trials received second-line treatment, while only 32% of the patients in the combination arm of docetaxel, cisplatin, and 5-FU (DCF) in the V325 study [5] received further chemotherapy. In the Japanese trials, the second-line regimen after the failure of the fi rst-line S-1 plus cisplatin combination was usually irinotecan-or taxane-based. To establish a standard second-line treatment, several Japanese study groups are now conducting randomized trials using these two agents in the second-line setting.
Several points should be clarifi ed in conducting these studies. The defi nition of "refractory" to fi rst-line therapy should be clear, and the eligibility criteria should be clearly defi ned to indicate whether or not patients who were intolerant to the fi rst-line therapy could be included. The primary endpoint is another important issue. Although there are several diffi culties to be overcome, overall survival seems to be a more reasonable endpoint than PFS in second-line studies.
There are several disparities between Japan and other countries in the treatment of advanced gastric cancer. Several candidate standard regimens for advanced gastric cancer have been reported based on randomized trials outside Japan. Only the combination of docetaxel, cisplatin, and 5-FU (DCF) regimen has shown significant prolongation of survival as compared with cisplatin plus 5-FU (CF) [5] , which is the most commonly used regimen worldwide. However, the advantage of DCF over CF seemed to be marginal, and the DCF regimen was associated with substantial toxicities. Other combination regimens such as irinotecan plus 5-FU/leucovorin and capecitabine plus cisplatin could also be possible alternative standards, but a survival advantage of these regimens over the CF regimen has not yet been confi rmed. The median PFS (or time to progression) of these candidate regimens, including that of S-1 plus cisplatin, were similar, with medians of around 5 to 6 months. Although future direct comparisons between these regimens are desirable, such studies seem less meaningful for investigators in the era of the global development of numerous new agents. At present, combinations of FUs and platinum compounds are considered to be the most reasonable standard for advanced gastric cancer, and these combinations could be the baseline regimens in future randomized trials incorporating new agents. Considering these circumstances, S-1 has a disadvantage compared with other agents, because there are ethnic differences in the ways that S-1 is metabolized, leading to differences in dose tolerance and toxicity [8, 9] . The tolerable dose of S-1 was substantially lower in Western than in Japanese patients, and this has resulted in lower acceptance of S-1 in Western countries. The FLAGS trial may resolve such issues related to ethnic differences. However, even if the FLAGS trial shows a survival advantage of S-1 + cisplatin over CF, the differences in the dose and schedule of this combination between this trial and those in the SPIRITS trial will remain an unavoidable issue if the S-1 + cisplatin arm is to become a reference arm in an international study. It seems to be necessary to adjust for these differences, other than the dose of S-1, such as the dose of cisplatin and the course intervals. Such a dose-fi nding study could also be a key for this combination to become a globally accepted standard regimen.
Incorporation of new agents
During the past few decades, signifi cant progress in tumor biology research has led to remarkable developments of new agents that target critical aspects of oncogenic pathways. Many molecular targeting agents have already been shown to have signifi cant clinical effects on various tumor types, such as hematological malignancies; colorectal, breast, and renal cell cancers; and gastrointestinal tumors (such as gastrointestinal stromal tumors; GISTs). The incorporation of these biological agents is also being investigated in the treatment of patients with gastric cancer.
Agents targeting the human epidermal growth factor receptor (HER) family
The HER family is a family of transmembrane tyrosine kinase growth factor receptors, including HER-1 [cerbB-1; epidermal growth factor receptor (EGFR)], HER-2 (c-erbB-2), HER-3 (c-erbB-3), and HER-4 (cerbB-4). These receptors regulate signal transduction in various cellular processes, including proliferation, differentiation, and cell survival [10] . EGFR is commonly overexpressed in gastrointestinal malignancies and its overexpression is associated with a more aggressive phenotype and poorer survival, which suggests that EGFR could be a rational therapeutic target [11, 12] . Gefi tinib, a small-molecule tyrosine kinase inhibitor (TKI) of EGFR, was fi rst investigated as monotherapy for gastric cancer in a Japan-Europe joint phase II study (Table 2 ) [13] . This study demonstrated very modest activity, with stable disease (SD) in only 18% and no confi rmed responses. A phase II study of erlotinib, another EGFR-TKI, showed modest activity, with a response rate of 9% [14] . However, all of the responders were patients with gastroesophageal junction carcinoma, and no patients with conventional gastric cancer achieved an objective response. In Japan, a phase I study of matuzumab (a humanized IgG1 monoclonal antibody) was conducted for patients with advanced solid cancers [15] . Two of the 26 patients achieved a partial response (PR), but no PR or stable disease (SD) was observed in the 7 patients with gastric cancer. Based on these results, it appears that EGFR-targeted agents have very modest activity as monotherapy against gastric cancer, and these agents are now under evalua- A phase I study of matuzumab in combination with epirubucin, cisplatin, and capecitabine (ECX) has also shown promising activity [17] and the phase I study of this combination was followed by a randomized phase II trial comparing the matuzumab combination with ECX alone. Trastuzumab is a humanized anti-HER2 monoclonal antibody that has been widely accepted as a standard agent for treating HER-2-positive breast cancer. This agent is now being evaluated for treating gastric cancer as well, in a global randomized trial based on the examination of HER-2 overexpression in gastric cancer tissues, with approximately 20% of these tissues being HER-2-positive [18] . This study, in which more than 120 institutions from 24 countries -including Japan and Korea -are participating, compares capecitabine plus cisplatin alone with capecitabine plus cisplatin plus trastuzumab (Table 3) .
Lapatinib is a dual inhibitor of the tyrosine kinase domains of HER-1 and HER-2; it acts by interfering with adenosine triphosphate binding. Clinical data have shown that lapatinib is active against HER-2-positive breast cancer as monotherapy and in combination with capecitabine [19] . A single-agent phase II study of lapatinib demonstrated very modest activity, with a response rate of only 5%, in unselected patients with metastatic gastric cancer [20] . A combination phase I study of lapatinib and weekly paclitaxel is now underway in Japan, and a subsequent randomized trial comparing this combination with paclitaxel alone in patients with HER-2-positive metastatic gastric cancer, in a second-line setting, is being planned.
Agents targeting vascular endothelial growth factor (VEGF) pathways
VEGF is one of the most potent proangiogenic growth factors expressed in most solid tumors and tumor stromal cells, and VEGF expression correlates with advanced stage and poor prognosis [21] . Bevacizumab is a humanized monoclonal antibody that targets VEGF. Significant survival prolongation has been reported in patients treated with this agent combined with cytotoxic chemotherapy for metastatic colorectal cancer. This improvement was subsequently observed in patients with breast and non-small cell lung cancers. A phase II study of bevacizumab in combination with irinotecan and cisplatin was conducted in patients with gastric cancer, and demonstrated promising activity, with a response rate of 65% and a median TTP of 8.3 months (Table 4) [22] . Several serious adverse events related to bevacizumab occurred during this study. Two (4%) of the 47 patients developed gastric perforation [1 (2%) with acute myocardial infarction], and 12 (25%) patients developed grade 3 or 4 venous thrombosis, though in 8 of them, this was incidentally detected on a routine protocolspecifi ed computed tomography (CT) scan. Another small phase II study of this agent, in combination with docetaxel, in patients with previously treated esophageal and gastric cancers, also showed promising activity, with a 27% response rate in the preliminary analysis [23] . Based on these preliminary results, a randomized trial evaluating the effi cacy of bevacizumab was initiated in 2007 as an international investigational new drug (IND), registration study including Japan and Korea. This study, named the Avastin in gastric cancer (AVAGAST) study, with a sample size of 760, is comparing capecitabine plus cisplatin alone with capecitabine plus cisplatin in combination with bevacizumab as fi rst-line therapy. In a perioperative setting, another randomized trial, comparing ECX with ECX plus bevacizumab, is being planned in the United Kingdom.
Several agents with a multitarget inhibitory mechanism that includes the inhibition of VEGF-receptor TK have also been developed for other tumor types. Sunitinib has shown signifi cant activities against renal cell cancer and imatinib-resistant GIST, and it has been approved for the treatment of these cancers. A singleagent phase II study of sunitinib for the treatment of advanced gastric cancer in the second-line setting was conducted predominantly in East Asian countries, including Japan [24] . Of the 42 patients registered, 2 (5%) patients achieved a PR, 15 (36%) had SD, 16 (38%) patients showed disease progression, and it was too early to evaluate the remaining 9 patients. This agent is now being evaluated in combination with standard chemotherapy regimens, such as capecitabine plus cisplatin, and S-1 plus cisplatin. Another multitarget TKI, sorafenib, combined with S-1 plus cisplatin, is also being investigated, in a Japan-Korea phase I/II study. VEGF trap (afl ibercept) is a potent anti-VEGF angiogenesis inhibitor protein that traps circulating VEGF [25] . This agent is in the developmental stage globally, and two phase I studies, one study of the agent in combination with S-1 and another in combination with docetaxel, are now underway in Japan.
Other targeting agents
In a single-agent phase II study of gefi tinib, pharmacodynamic studies of serial tumor biopsy specimens were conducted [26] . Overall, the intratumoral phosphorylation of mitogen-activated protein kinase (pMAPK) and the production of phosphorylated Akt (pAkt) were not signifi cantly inhibited by gefi tinib. However, decreases in pAkt were correlated with enhanced apoptosis. Similar results were seen in a phase I study of matuzumab: inhibition of pAkt was achieved in patients who responded to matuzumab, though the sample number was small. These results suggest that pAkt has a key role in cell survival and clinical response. Another agent being investigated, RAD001, is an oral inhibitor of mTOR (mammalian target of rapamycin), which is located downstream in the Akt pathway [27] . A phase II study of this agent is now underway in Japan after a remarkable response was achieved in patients with metastatic gastric cancer in the previous phase I study.
The c-met protooncogene encodes a transmembrane tyrosine kinase receptor (Met) for hepatocyte growth factor/scatter factor (HGF/SF). A high level of c-Met expression has been correlated with the metastatic spread of tumors and poor survival in patients with various types of tumors, including gastric cancer [28] ; this fi nding suggested c-Met as a therapeutic target for gastric cancer. Several agents targeted to c-Met are in the early developmental stage. Among these agents, MK2461, a TKI for activated c-Met, is now under evaluation in a joint Japan-Korea phase I study.
Nuclear factor (NF)-κB is a family of inducible transcription factors found ubiquitously in all cells; NF-κB mediates the expression of genes involved in tumor promotion, angiogenesis, metastasis, cell proliferation, and inhibition of apoptosis. High expression of NF-κB is known to be associated with increased tumor size, lymphatic invasion, metastasis, and poor survival [29] . Potential targeted therapies for NF-κB inhibition include the proteasome inhibitor bortezomib. A phase II trial of bortezomib with and without irinotecan has been reported; response rates of 33% and 9%, respectively, and MSTs of 4.8 and 5.4 months, respectively, were observed [30] . However, as there were some serious toxicities and the study population was heterogeneous, it seems hard to evaluate the results of this study.
Conclusion
There are two major approaches to achieve further progress in the treatment of advanced gastric cancer in future studies. The fi rst one is to optimize the use of conventional cytotoxic agents (regimens) in the continuum of treatment for the disease, including second-line studies. The second approach is to incorporate new active agents, particularly molecular targeting agents. Several molecular targeting agents that have shown survival advantages in patients with other tumor types are now under investigation for the treatment of advanced gastric cancer in international randomized trials including Japan and Korea. Next-generation molecular tar- GEJ, Gastroesophageal junction carcinoma; mTTP; median time to progression; MST, median survival time; CR, complete response; PR, partial response; SD, stable disease geting agents are also being evaluated in early clinical studies. Although some biological differences between conventional gastric cancer and gastroesophageal junction carcinoma have been shown in response to molecular targeting agents, the question of whether or not these differences truly exist will be clarifi ed by ongoing global randomized studies. In any event, the development of new targeting agents will improve our understanding of the distinct biology of gastric cancer. Gastric cancer has a high incidence in Japan and Korea, and biological studies would be advantageous for developing new targeting agents. For biological studies, the tumor tissues are easily obtainable via endoscopy, and, such studies may constitute new frontiers in biological therapy. We expect that these efforts will provide not only further clinical advantages but that they will also lead to tailored medicine.
